Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 10Active not recruiting 5Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Head & Neck 1

Conditions

Prostatic Neoplasms 3Salivary Gland Neoplasms 1Biochemically Recurrent Prostate Cancer 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 94Biopsy 60pembrolizumab 58Carboplatin 57Cisplatin 51Nivolumab 47Cyclophosphamide 40Radiotherapy 39Paclitaxel 37Gemcitabine 34Dexamethasone 34Bevacizumab 31Radiation 30atezolizumab 29Pemetrexed 28venetoclax 25olaparib 25Etoposide 25X-Rays 24Prednisone 23Immunoglobulin G 23Doxorubicin 23Disulfides 23Vincristine 22Lenalidomide 22Leucovorin 21Ipilimumab 21durvalumab 20Taxes 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × darolutamide × 30 days × Clear all
NCT05669664 2026-06-11

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
21 enrolled
Head & Neck

Salivary Gland Neoplasms

NCT05367440 2026-06-01

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT04070209 2026-05-27

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2 Active not recruiting
66 enrolled
Genitourinary

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

AstraZeneca

Phase 3 Active not recruiting
1,889 enrolled
Genitourinary

Prostatic Neoplasms

NCT05794906 2026-05-19

ARASTEP

Bayer

Phase 3 Active not recruiting
985 enrolled
Genitourinary

Biochemically Recurrent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡